search
Back to results

Cyanoacrylate Closure for Treatment of Venous Leg Ulcers

Primary Purpose

Venous Leg Ulcer

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Cyanoacrylate closure
Sponsored by
Sunnybrook Health Sciences Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Venous Leg Ulcer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥18 years old at time of screening;
  2. Venous leg ulcer;
  3. Venous insufficiency (>0.5 seconds; confirmed by Doppler within last 6 months);
  4. ABI of ≥0.9;
  5. Capable of understanding the study and providing informed consent.

Exclusion Criteria:

  1. Previous hypersensitivity reactions to the VenaSealTM adhesive or cyanoacrylates;
  2. Acute superficial thrombophlebitis;
  3. Bilateral treatment
  4. Thrombophlebitis migrans;
  5. Deep venous thrombosis;
  6. Deep venous incompetence or occlusion in external iliac or distal veins in the affected extremity (as assessed based on spontaneity, phasicity, augmentation, pulsatility, and compressibility on ultrasound);
  7. Post-thrombotic syndrome;
  8. Acute sepsis;
  9. Coagulation disorders;
  10. Radiation or chemotherapy within 3 months of study;
  11. Pregnant or lactating females;
  12. Uncontrolled diabetes (HbA1c >10%);
  13. Diabetic foot ulcers;
  14. Current use of systemic anticoagulation;
  15. Previous treatment of target vein;
  16. Tortuous veins;
  17. Current participation in another interventional study, or participation within 30 days prior to screening;
  18. Inability to tolerate compression, or to receive endovenous treatment.

Sites / Locations

  • Sunnybrook Health Sciences Centre

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cyanoacrylate closure

Arm Description

Subjects enrolled in the study will undergo ultrasound guided vein closure using the VenaSealTM cyanoacrylate delivery device.

Outcomes

Primary Outcome Measures

Rate of adverse events
Healing rate
Change in ulcer size

Secondary Outcome Measures

Rate of adverse events
Healing rate
Change in ulcer size
Closure rate
Time to ulcer closure
Patient-reported quality of life: EuroQol Five Dimension Scale: EQ-5D-5L Health Questionnaire
EuroQol Five Dimension Scale: EQ-5D-5L Health Questionnaire - measures patient-reported health related to five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses for each parameter are coded 1-5, with a lower score reflecting better health, and a higher score meaning worse health. Overall health is self-rated on a scale 0-100, with 0 meaning the worst and 100 meaning the best health imaginable.

Full Information

First Posted
July 5, 2019
Last Updated
April 12, 2023
Sponsor
Sunnybrook Health Sciences Centre
Collaborators
Medtronic Vascular
search

1. Study Identification

Unique Protocol Identification Number
NCT04011371
Brief Title
Cyanoacrylate Closure for Treatment of Venous Leg Ulcers
Official Title
Cyanoacrylate Closure for Treatment of Venous Leg Ulcers
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
September 1, 2019 (Actual)
Primary Completion Date
June 1, 2022 (Actual)
Study Completion Date
June 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sunnybrook Health Sciences Centre
Collaborators
Medtronic Vascular

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Venous leg ulcers (VLUs) are a common wound with significant morbidity and cost, and suboptimal therapeutic options. VLUs result from chronic venous insufficiency, including venous reflux and post-thrombotic syndrome. VLU can take from months to years to heal, and 54-78% recur. Current therapies include wound, compression therapy, and medications. These treatments can increase the rate of healing, and reduce recurrence, however these therapies can be burdensome, painful, and ineffective, and despite these therapies, ~50% of wounds become chronic. Chronic VLUs can be painful, malodorous, and infected, and they often significantly limit an individual's function and mobility. An emerging therapy for symptomatic venous reflux is the closure of the culprit vein by endovenous closure with a cyanoacrylate adhesive implant. Recent studies show cyanoacrylate closure (CAC) to be a safe and effective treatment for varicosities resulting from symptomatic incompetent great saphenous veins. This study will evaluate the safety and effectiveness of CAC for VLUs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Leg Ulcer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cyanoacrylate closure
Arm Type
Experimental
Arm Description
Subjects enrolled in the study will undergo ultrasound guided vein closure using the VenaSealTM cyanoacrylate delivery device.
Intervention Type
Procedure
Intervention Name(s)
Cyanoacrylate closure
Intervention Description
Cyanoacrylate glue embolization targeting venous insufficiency
Primary Outcome Measure Information:
Title
Rate of adverse events
Time Frame
3 months
Title
Healing rate
Description
Change in ulcer size
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Rate of adverse events
Time Frame
12 months
Title
Healing rate
Description
Change in ulcer size
Time Frame
12 months
Title
Closure rate
Description
Time to ulcer closure
Time Frame
12 months
Title
Patient-reported quality of life: EuroQol Five Dimension Scale: EQ-5D-5L Health Questionnaire
Description
EuroQol Five Dimension Scale: EQ-5D-5L Health Questionnaire - measures patient-reported health related to five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses for each parameter are coded 1-5, with a lower score reflecting better health, and a higher score meaning worse health. Overall health is self-rated on a scale 0-100, with 0 meaning the worst and 100 meaning the best health imaginable.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years old at time of screening; Venous leg ulcer; Venous insufficiency (>0.5 seconds; confirmed by Doppler within last 6 months); ABI of ≥0.9; Capable of understanding the study and providing informed consent. Exclusion Criteria: Previous hypersensitivity reactions to the VenaSealTM adhesive or cyanoacrylates; Acute superficial thrombophlebitis; Bilateral treatment Thrombophlebitis migrans; Deep venous thrombosis; Deep venous incompetence or occlusion in external iliac or distal veins in the affected extremity (as assessed based on spontaneity, phasicity, augmentation, pulsatility, and compressibility on ultrasound); Post-thrombotic syndrome; Acute sepsis; Coagulation disorders; Radiation or chemotherapy within 3 months of study; Pregnant or lactating females; Uncontrolled diabetes (HbA1c >10%); Diabetic foot ulcers; Current use of systemic anticoagulation; Previous treatment of target vein; Tortuous veins; Current participation in another interventional study, or participation within 30 days prior to screening; Inability to tolerate compression, or to receive endovenous treatment.
Facility Information:
Facility Name
Sunnybrook Health Sciences Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N3M5
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
8156326
Citation
Callam MJ. Epidemiology of varicose veins. Br J Surg. 1994 Feb;81(2):167-73. doi: 10.1002/bjs.1800810204.
Results Reference
result
PubMed Identifier
11510598
Citation
Fowkes FG, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. Angiology. 2001 Aug;52 Suppl 1:S5-15. doi: 10.1177/0003319701052001S02.
Results Reference
result
PubMed Identifier
9821029
Citation
Van den Oever R, Hepp B, Debbaut B, Simon I. Socio-economic impact of chronic venous insufficiency. An underestimated public health problem. Int Angiol. 1998 Sep;17(3):161-7.
Results Reference
result
PubMed Identifier
15941430
Citation
Abbade LP, Lastoria S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol. 2005 Jun;44(6):449-56. doi: 10.1111/j.1365-4632.2004.02456.x.
Results Reference
result
PubMed Identifier
10355863
Citation
Olin JW, Beusterien KM, Childs MB, Seavey C, McHugh L, Griffiths RI. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med. 1999;4(1):1-7. doi: 10.1177/1358836X9900400101.
Results Reference
result
PubMed Identifier
7856198
Citation
Mayer W, Jochmann W, Partsch H. [Varicose ulcer: healing in conservative therapy. A prospective study]. Wien Med Wochenschr. 1994;144(10-11):250-2. German.
Results Reference
result
PubMed Identifier
10194512
Citation
Bergqvist D, Lindholm C, Nelzen O. Chronic leg ulcers: the impact of venous disease. J Vasc Surg. 1999 Apr;29(4):752-5. doi: 10.1016/s0741-5214(99)70330-7. No abstract available.
Results Reference
result
PubMed Identifier
10396491
Citation
Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health. 1999 Mar;53(3):149-53. doi: 10.1136/jech.53.3.149.
Results Reference
result
PubMed Identifier
17156107
Citation
Lazarus GS, Cooper DM, Knighton DR, Percoraro RE, Rodeheaver G, Robson MC. Definitions and guidelines for assessment of wounds and evaluation of healing. Wound Repair Regen. 1994 Jul;2(3):165-70. doi: 10.1046/j.1524-475X.1994.20305.x.
Results Reference
result
PubMed Identifier
26025146
Citation
Kelechi TJ, Johnson JJ, Yates S. Chronic venous disease and venous leg ulcers: An evidence-based update. J Vasc Nurs. 2015 Jun;33(2):36-46. doi: 10.1016/j.jvn.2015.01.003.
Results Reference
result
PubMed Identifier
25650040
Citation
Morrison N, Gibson K, McEnroe S, Goldman M, King T, Weiss R, Cher D, Jones A. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015 Apr;61(4):985-94. doi: 10.1016/j.jvs.2014.11.071. Epub 2015 Jan 31.
Results Reference
result
PubMed Identifier
26992340
Citation
Almeida JI, Javier JJ, Mackay E, Bautista C, Proebstle TM. First human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2013 Apr;1(2):174-80. doi: 10.1016/j.jvsv.2012.09.010. Epub 2012 Dec 22.
Results Reference
result
PubMed Identifier
26992985
Citation
Proebstle TM, Alm J, Dimitri S, Rasmussen L, Whiteley M, Lawson J, Davies A. Twelve-Month Follow-up of the European Multicenter Study on Cyanoacrylate Embolization of Incompetent Great Saphenous Veins. J Vasc Surg Venous Lymphat Disord. 2014 Jan;2(1):105-6. doi: 10.1016/j.jvsv.2013.10.009. Epub 2013 Dec 12. No abstract available.
Results Reference
result

Learn more about this trial

Cyanoacrylate Closure for Treatment of Venous Leg Ulcers

We'll reach out to this number within 24 hrs